SiNtx Technologies, Inc. SINT 深 滬
等待開盤 10-08 09:30:00 美东时间
2.17
-0.010
-0.46%
華盛通- 最 高2.20
- 今 開2.12
- 成交量 4.09万股
- 最 低 2.0501
- 昨 收 2.18
- 總市值 1446.20万
- 52周最高 4.46
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 1.40
- 委 比 -99.43%
- 總股本 666.45万
- 歷史最高 209400.00
- 量 比 0.19
- 振 幅 6.88%
- 歷史最低 1.40
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Sintx Technologies Reports Surging Preliminary Third-Quarter Revenue
Sintx Technologies ( ($SINT) ) just unveiled an update. In a press release date...
10-01 21:25
SINTX Reports Preliminary Q3 Revenue of $2.2M, Exceeding High End Of Company’s Previously Announced Guidance Of $0.9M-$1.1M
Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technolo...
10-01 21:10
Ascendiant Capital Maintains Buy on SINTX Technologies, Raises Price Target to $12.5
Ascendiant Capital analyst Edward Woo maintains SINTX Technologies (NASDAQ:SINT) with a Buy and raises the price target from $12 to $12.5.
10-01 17:23
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
SINTX Technologies reported third-quarter revenue of $2.2 million, surpassing its guidance of $0.9 million to $1.1 million, driven by strong industrial sales to Fortune 500 aerospace subsidiaries. Revenue grew approximately 380% from the second quarter and over ten times compared to the prior year. The company reaffirmed its fourth-quarter revenue guidance and noted that $2.1 million of the third-quarter revenue qualifies it to exercise Class B w...
10-01 13:00
SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts
SINTX Technologies, Inc. has announced a Masterclass hosted by Orthopedics This Week, featuring experts discussing the potential of silicon nitride in orthopedic applications. The session highlights silicon nitride's advantages over traditional materials like PEEK and titanium, focusing on its bone-cell response, surface chemistry, and antibacterial properties. SINTX is expanding silicon nitride's use in spine, foot, and ankle markets, leveraging...
09-14 13:00
SINTX regains Nasdaq compliance
SINTX Technologies (SINT) said Thursday it regained compliance with Nasdaq's minimum stockholders' equity requirement after reporting equity of about $4.83M as of June 30. Nasdaq said the previously ...
08-13 21:50
SINTX Regains Nasdaq Compliance, Supporting Growth Initiatives
The latest update is out from Sintx Technologies ( ($SINT) ). On August 12, 202...
08-13 21:28
SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement
SINTX Technologies has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, as confirmed by its Q2 2026 report showing $4.83 million in equity. The company is now resolved to focus on commercializing its silicon nitride technologies and executing its growth strategy.
08-13 13:00
SINTX Technologies Q2 EPS $(0.75) Misses $(0.66) Estimate, Sales $452.000K Beat $406.667K Estimate
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 13.64 percent. This is a 17.58 percent increase over losses of $(0.91) per share from the same period last year. The company reported quarterly sales of $452.000 ...
08-12 04:09
